These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript.pdf (1001.76 kB)

The Synthesis of Peptide-Conjugated Poly(2-Ethyl-2-Oxazoline)-bpoly(L-Lactide) (PEtOx-B-PLA) Polymeric Systems Through the Combination of Controlled Polymerization Techniques and Click Reactions

submitted on 23.06.2020, 12:09 and posted on 25.06.2020, 06:35 by Umut Ugur Ozkose, Sevgi Gulyuz, Melek Parlak Khalily, Salih Ozcubukcu, Asuman Bozkır, Mehmet Atilla Taşdelen, onur alpturk, Özgür Yılmaz
To optimize the therapeutic effect of pharmaceutical agents, drug delivery systems tailored from FDA-approved polymers like poly(L-lactide) (PLA) is an effective strategy. Because of their hydrophobic character, these systems greatly suffer from reduced circulation time thus, amphiphilic block copolymers became favourable to overcome this limitation. Of them, poly(oxazoline)-b-poly(L-lactide) are of choice as poly(oxazoline) (PEtOx) is compatibile, biodegradable, while exhibiting minimum cytotoxicity. To tailor selective drug targeting drug delivery systems, whereby their selectivity for tumour tissues is maximised, these polymers should be decorated with so-called tumour-homing agents, such as antibodies, peptides and so forth. To this respect, we designed a new block copolymer, allyl-poly(2-ethyl-2-oxazoline)-b-poly(L-lactide) allyl-(PEtOx-b-PLA) and its subsequent conjugation to tumour-homing peptides, peptide-18 and peptide-563 at the terminal position. In this manuscript, we report our synthetic route to obtain this building block and its conjugation to tumour-homing agents.


This research is supported by the Scientific and Technological Research Council of Turkey (TUBITAK) (grant number: 213M725).


Email Address of Submitting Author


Materials Institute, Marmara Research Center, TUBITAK, Kocaeli



ORCID For Submitting Author

Declaration of Conflict of Interest

No conflict of interest